Nuclear-fuel market. It supplies low-enriched uranium, the standard fuel for commercial reactors, and operates the only U.S. Facility licensed to enrich uranium to the higher concentrations required for high-assay low-enriched uranium, or HALEU. The Piketon, Ohio, plant is also the first U.S. -owned enrichment facility to begin production since the 1950s.
The company’s domestic production push follows years in which it shut down U.S. Enrichment operations and relied more heavily on imported material. The United States’ 2024 law banning Russian uranium imports, subject to limited waivers, and Russia’s subsequent restrictions on exports have increased pressure to rebuild domestic capacity.
Centrus produced 900 kilograms of HALEU by June 2025 under a Department of Energy demonstration program. The project uses a cascade of 16 advanced centrifuges, and the material is intended for fuel qualification and testing by advanced-reactor developers.
The opportunity is large but the timing is uncertain. Centrus reported $4. 5 billion of backlog at June 30, 2026, extending to 2040. The LEU segment represented about $3. 7 billion, while Technical Solutions contributed about $800 million. However, roughly $3 billion of the LEU backlog consisted of contingent sales contracts and commitments tied to potential expansion at Piketon, and the company warned that backlog is not guaranteed to become revenue or profit.
Centrus said future results also depend on additional government task orders, appropriations, customer demand, construction progress and the availability of capital for expansion.
That leaves Centrus with an unusual combination of strategic scarcity and near-term execution risk. Its backlog provides visibility into potential long-term demand, while the transition away from Russian supply and the restart of domestic enrichment could create opportunities. But contingent commitments, government funding and the slow buildout of commercial capacity mean the backlog cannot be treated as immediate earnings. On the supplied financial outlook, revenue and net income are expected to weaken between 2025 and 2028, even as the company works to convert contracts into deliveries.
At about 40 times projected earnings for the following year, the shares already reflect substantial optimism. Centrus may remain a key U.S. Nuclear-fuel supplier, but the verified record supports a measured conclusion: its strategic position and multibillion-dollar backlog offer long-term potential, while the path to exceptional shareholder returns remains dependent on production scale-up, contract execution and government support.